Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer

被引:0
|
作者
Jiang, Yupeng [1 ]
Liu, Yuyao [2 ]
Huang, Hong [3 ]
Zhao, Tiantian [1 ]
Zhao, Zengyi [1 ]
Gao, Yawen [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China
[2] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Oncol, Changsha 410004, Peoples R China
[3] Guilin Med Univ, Guilin 541000, Peoples R China
关键词
RAS mutation; High microsatellite instability; Deficient mismatch repair; Colorectal cancer; Tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR-DEFICIENT; DENDRITIC CELLS; MICROSATELLITE INSTABILITY; KRAS MUTATION; E-SELECTIN; OPEN-LABEL; MICROENVIRONMENT; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I
10.1007/s00262-024-03926-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeMicrosatellite high instability/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) has an active tumor microenvironment, rendering it more sensitive to immune checkpoint inhibitors. Given that studies involving patients with MSI-H colorectal cancer with RAS mutations are scarce, we explored the effect of RAS mutations on the TME in patients with MSI-H/dMMR cancer and identified potential prognostic factors.MethodsSeventy-five patients diagnosed with MSI-H/dMMR colorectal cancer were retrospectively enrolled and divided into RAS-mutant and -wild-type groups. The expression levels of CD11c+ dendritic cells, CD4+ T cells, CD8+ T cells, and regulatory T cell (Treg) markers were detected, and prognostic factors were analyzed.ResultsRAS-mutant MSI-H colorectal patients were more likely to have: (1) higher platelet values; (2) shorter disease-free survival (DFS); (3) lower infiltrated numbers of CD11c+ dendritic cells, CD4+ T lymphocytes, and CD8+ T lymphocytes, and higher infiltrated numbers of Foxp3+ Treg cells. In MSI-H/dMMR CRC patients: (1) the high CD11c + , CD4 +, and CD8 + cells infiltration group had longer DFS than the low-infiltration group, and Foxp3 + cells infiltration was not significantly correlated with DFS; (2) the RAS mutation status, number of CD11c+ cells infiltrated, and carbohydrate antigen 19-9 (CA19-9) level were the potential prognostic factors.ConclusionRAS mutations in patients with MSI-H/dMMR CRC may reduce the infiltration of CD11c+ dendritic cells, CD4+ T cells, and CD8+ T cells, and increase the infiltration of Foxp3+ Treg cells to affect the tumor microenvironment of patients. RAS gene status, CD11c + cells infiltration, and CA19-9 level were potential prognostic factors for MSI-H/dMMR CRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
    Inamori, Koji
    Togashi, Yosuke
    Fukuoka, Shota
    Akagi, Kiwamu
    Ogasawara, Kouetsu
    Irie, Takuma
    Motooka, Daisuke
    Kobayashi, Yoichi
    Sugiyama, Daisuke
    Kojima, Motohiro
    Shiiya, Norihiko
    Nakamura, Shota
    Maruyama, Shoichi
    Suzuki, Yutaka
    Ito, Masaaki
    Nishikawa, Hiroyoshi
    JCI INSIGHT, 2021, 6 (09)
  • [2] Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients
    Margalit, Ofer
    Stemmer, Amos
    Chapin, William J.
    Shacham-Shmueli, Einat
    Kopetz, Scott
    Andre, Thierry
    Overman, Michael J.
    Pietrantonio, Filippo
    Boursi, Ben
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [3] Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
    Qi Zhang
    Jian Li
    Lin Shen
    Yongsheng Li
    Xicheng Wang
    Cancer Biology & Medicine, 2023, 20 (10) : 706 - 712
  • [4] Immunotherapy Promising for Metastatic MSI-H/dMMR Colorectal Cancer
    Yarden, Ronit
    ONCOLOGY-NEW YORK, 2019, 33 (05): : 179 - 179
  • [5] BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
    Colle, Raphael
    Lonardi, Sara
    Cachanado, Marine
    Overman, Michael J.
    Elez, Elena
    Fakih, Marwan
    Corti, Francesca
    Jayachandran, Priya
    Svrcek, Magali
    Dardenne, Antoine
    Cervantes, Baptiste
    Duval, Alex
    Cohen, Romain
    Pietrantonio, Filippo
    Andre, Thierry
    ONCOLOGIST, 2023, 28 (09): : 771 - 779
  • [6] Opportunities and challenges of immunotherapy for dMMR/ MSI-H colorectal cancer
    Zhang, Qi
    Li, Jian
    Shen, Lin
    Li, Yongsheng
    Wang, Xicheng
    CANCER BIOLOGY & MEDICINE, 2023, 20 (10) : 706 - 712
  • [7] Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
    Qi Zhang
    Jian Li
    Lin Shen
    Yongsheng Li
    Xicheng Wang
    Cancer Biology & Medicine, 2023, (10) : 706 - 712
  • [8] Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
    Nasca, Vincenzo
    Barretta, Francesco
    Corti, Francesca
    Lonardi, Sara
    Niger, Monica
    Elez, Maria Elena
    Fakih, Marwan
    Jayachandran, Priya
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Cremolini, Chiara
    Ros, Javier
    Ambrosini, Margherita
    Mazzoli, Giacomo
    Intini, Rossana
    Overman, Michael J.
    Miceli, Rosalba
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [9] Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
    Nasca, Vincenzo
    Barretta, Francesco
    Corti, Francesca
    Lonardi, Sara
    Niger, Monica
    Elez, Maria Elena
    Fakih, Marwan
    Jayachandran, Priya
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Cremolini, Chiara
    Ros, Javier
    Ambrosini, Margherita
    Mazzoli, Giacomo
    Intini, Rossana
    Overman, Michael J.
    Miceli, Rosalba
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [10] Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
    Mulet-Margalef, Nuria
    Linares, Jenniffer
    Badia-Ramentol, Jordi
    Jimeno, Mireya
    Monte, Carolina Sanz
    Mozo, Jose Luis Manzano
    Calon, Alexandre
    CANCERS, 2023, 15 (04)